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Abstract 
 
Efficient mitochondrial gene delivery is a technique with great biomedical potential, due 
to the possibility of using it for the treatment of many pathologies, currently without cure. Among 
many other types of vectors, surfactant and lipid-based systems stand out as an efficient, safe 
and biocompatible strategy to integrate new DNA in the existing mitochondrial genome. 
The aim of this work was to determine the physicochemical properties, transfection 
efficiency and cytotoxicity of novel serine-based gemini surfactants. Gemini are a class of 
surfactants containing two polar head groups and two hydrocarbon chains (n) linked by a spacer 
(s) at the headgroup level. 
 In this work, a series of four different serine-based gemini surfactants, all with a 12 carbon 
long alkyl spacer (n-12-n), and hydrocarbon chains containing n = 12, 14, 16 and 18 carbons, 
were successfully synthesized. The critical micelle concentration and other interfacial parameters 
of these compounds were determined by tensiometry, and several unusual and interesting trends 
were obtained. 
 These novel gemini surfactants were further used to prepare binary gemini/DNA and 
ternary gemini/DNA/helper lipid complexes with mtDNA, with several formulations, differing on 
the gemini:DNA (+/-) charge ratio. The transfection efficiency and cytotoxicity of the formulations 
were tested in vitro, in HeLa cell cultures. Both types of complexes were further characterized in 
terms of morphology, size and zeta potential. The various formulations of complexes containing 
gemni surfactants were shown to have distinctive transfection efficiencies and cytotoxicity, 
varying significantly with the presence of helper lipids. 
 This work is a contribution to the more global study of the relationships between the 
lengths of both spacer and hydrocarbon chain of gemini surfactants, on one side, and their effects 
on physicochemical properties and biological activity, on the other side, providing another piece 
of the puzzle in the rational design of novel gene delivery systems. 
 
 
Keywords: surfactant, gemini, serine, mitochondria, DNA, transfection, cytotoxicity, helper lipids, 
alkyl spacer, cmc  
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Resumo 
 
A terapia génica mitocondrial eficiente é uma técnica de elevado potencial biomédico, 
devido à possibilidade da sua utilização no tratamento de inúmeras patologias atualmente sem 
cura. Entre muitos outros tipos de vetores, os nanosistemas auto-agregados baseados em 
surfactantes e lípidos destacam-se como uma estratégia eficaz, segura e biocompatível para 
integrar novo DNA no genoma mitocondrial já existente.  
O objetivo deste trabalho consistiu na determinação de propriedades físico-químicas, 
citotoxicidade e eficiência de transfecção de novos surfatantes gemini derivados de serina. Os 
surfactantes gemini são uma classe de agentes tensioativos que contêm dois grupos polares 
ligados entre si por um espaçador covalente (s), e duas cadeias hidrocarbonadas principais (n). 
Neste trabalho, efetuou-se com sucesso a síntese de uma série de quatro surfactantes 
gemini diferentes, derivados de serina, todos com um espaçador de 12 carbonos (n-12-n) e 
cadeias hidrocarbonadas diferentes, com n = 12, 14, 16 e 18 carbonos. A concentração micelar 
crítica dos compostos e outros parâmetros interfaciais correlacionados foram determinados por 
tensiometria através do método da placa de Wilhelmy. Estes compostos demonstraram 
apresentar tendências pouco comuns e interessantes nas suas propriedades físico-químicas, em 
particular na dependência da cmc com o comprimento das cadeias hidrocarbonadas. 
Os novos surfactantes gemini foram posteriomente usados para preparar complexos 
binários gemini/DNA e ternários gemini/DNA/lípido auxiliare com mtDNA, de acordo com várias 
formulações, diferindo entre si na razão de carga (+/-) gemini:DNA. A citotoxicidade e eficiência 
de transfecção destas formulações foram testadas in vitro, usando culturas de células HeLa. 
Ambos os tipos de complexos foram ainda estruturalmente caracterizados pelo seu tamanho, 
morfologia e potencial zeta. As diferentes formulações de complexos demonstraram possuir 
eficiências de citotoxicidade e transfecção distintas, variando de forma significativa na presença 
de lípidos auxiliares.  
Este trabalho constitui um contributo para o estudo das relações entre o comprimento da 
cadeia hidrocarbonada e espaçador dos surfactantes gemini derivados de serina e os seus 
efeitos sobre as propriedade físico-químicas e atividade biológica, configurando-se assim como 
uma nova peça de puzzle no desenvolvimento racional de novos sistemas de terapia génica. 
 
 
Palavras-chave: surfatante, gemini, serina, mitocôndria, DNA, transfecção, citotoxicidade, 
lípidos auxiliares, espaçador, cmc 
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1.1 Mitochondrial gene therapy 
 
The mitochondrion is the cell organelle that produces most of the required energy 
under normal conditions. Therefore, its health is of paramount importance for the cell 
metabolism and the overall health and functional capacity of the organism. 
The mitochondrion is also unique as the sole organelle in human cells that 
contains its own DNA, separated from the nucleus, and as such possesses its own 
unique problems and pathologies. 
 
1.1.1 Mitochondrial diseases                                                                                                                                                  
 
Even though mitochondria have lost, in the process of evolution, most of their 
genes (coding proteins that mediate their function) to the cell’s nucleus, they still maintain 
a separate, albeit small, genome(3), as seen in Figure 1. 
 
 
Figure 1 - Representation of the mitochondrial genome and the zones corresponding to certain proteins. The 
orange zones correspond to the part of the mtDNA that encodes for the mitochondria specific ribosome 
subunits From ref(4). 
 
Mitochondrial diseases are caused by dysfunctions in the mitochondria’s normal 
metabolic processes, generating a measurable effect on the organism as a whole. These 
dysfunctions have varying degrees of severity and can lead to a vast array of 
pathologies, since mitochondria are important for many critical vital processes, such as 
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energy generation, apoptosis mediation, generation of signalling molecules, to cite a 
few.(5-6) 
Depending on the metabolic pathway affected these pathologies can range from 
immediately lethal to lifelong debilitating symptoms and reduced lifespan.(7-8) 
One of the first mitochondrial pathologies to be discovered is Leber’s hereditary 
optic neuropathy (LHON), a blindness with a sudden onset caused by a mtDNA 
missense mutation(9). Other examples of classic mitochondrion based diseases are 
chronic progressive external ophthalmopelia (CPEO)(9), Kearns-Sayre Syndrome 
(KSS)(10-11) and myoclonic epilepsy with ragged-red fibers (MERRF)(12). In Figure 2, one 
can see the location of some of the cited mutations in the mitochondrial genome. 
 
 
Figure 2 - Position in the mitochondrial genome of some well-known mutations. Adapted from ref(3). 
 
Recently, mitochondria have been linked to other diseases that until now were 
thought to unrelated to this organelle, such as Parkinson’s disease(13-14), diabetes 
melitus(15) and Alzheimer’s disease(16-17). 
Mitochondria are a center of high energy production; however, they use a process 
that generates copious amounts of reactive oxygen species (ROS), which are highly 
damaging to organic tissue and molecules, including DNA. These ROS are generated in 
very close proximity to the mitochondrial genetic material, which can induce mutations 
over time if the processes for ROS removal are not efficient.(8, 18) 
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1.1.2 Treating mitochondrial dysfunction 
 
Treating a mitochondrial dysfunction is not an easy task and over the years 
several strategies have been developed to prevent or treat the diseases caused. Three 
distinct methodologies arise, described as follows. 
Starting on the prevention front, there is a very recent technique that allows for a 
mother with a known mitochondrial dysfunction to have healthy children, free of the 
mother’s dysfunction or propensity to it. This technique consists of the donation of an 
oocyte with healthy mitochondria by another woman, which is then enucleated. The 
nucleus from the mother’s fertilized zygote is then transferred to the empty oocyte that 
in turn, is also potentially capable of forming a fully functioning embryo(19). A 
representation of this process can be seen on Figure 3. 
The ethical problems related to this process are, however, still subject to intense 
discussion.(20) 
 
Figure 3 - Representation of the mitochondrial donation process. In red are the mutated undesired 
mitochondria, and the healthy in green. The blue circles represent the mother's genetic material. From ref(19). 
 
Another pathway to treat these dysfunctions is the pharmacological path, which 
can be used to rectify the signalling from the mitochondrial pathways, either by blocking 
or activating proteins, in order to eliminate, modulate or reduce the symptoms caused by 
the dysfunctions.(21) 
The pharmacological path can be applied with more ease than any other, for well 
documented dysfunctions, but can also cause many undesired side effects. With recent 
developments, it is possible to reduce the intensity and incidence of the side effects with 
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drug delivery systems, by making the drug available only to the specific place of 
treatment.(22) 
Lastly, it is possible to treat mitochondrial dysfunctions by acting at the root of the 
problem: the mitochondrial DNA. While possible, it is no easy task to change the already 
existing DNA of a living multicellular being. On this respect, mtDNA is different from the 
regular cell’s DNA and this fact entails both advantages and disadvantages. 
The mitochondrial DNA exists inside the mitochondria itself in circular forms (like 
bacterial plasmids) and multiple copies exist at the same time in each mitochondrion(5). 
It is not condensed around histones like the nucleus’ DNA, making it more prone to 
changes. Its location inside the mitochondrion is both an advantage, since it makes it 
easier to have selectivity and no interference with regular DNA, and a disadvantage, as 
the mitochondrion membranes are more difficult to overcome than the nucleus’ porous 
membrane. The modification of the mitochondria mtDNA can be achieved through 
mitochondrial gene therapy, which will be discussed below. 
 
 
1.1.3 Workings of Mitochondrial Gene Therapy (MGT) 
 
Adhya et al define mitochondrial gene therapy as “a protocol for the treatment of 
mitochondrial dysfunctions using genetic material as the therapeutic agent, delivered to 
the appropriate sub-compartment of the mitochondria, improving its function and having 
a measurable clinical effect”(5). The genetic material used can be of various natures: 
DNA, RNA and their derivatives. 
Inside each mitochondrion there are between 1000 and 5000 copies of circular 
mtDNA that mutate independently. A certain threshold of mutated copies must be 
reached for a dysfunction to manifest itself(23). This is called heteroplasmy and varies 
with the individual in terms of number of mutated copies required(24). This threshold can 
be overcome in two distinct manners in a single organism over its lifetime, through the 
vegetative and relaxed replication of mtDNA(25). Vegetative replication occurring during 
mitosis and subsequent division of mitochondria, has the potential to both eliminate the 
mutation over time or increase the number of mutated plasmids. At all points of the cell’s 
cycle, mtDNA is constantly turned over, with random plasmids being replicated – relaxed 
replication – which can lead over time to the propagation of mutated plasmids and onset 
of mitochondrial disease. Both vegetative and relaxed replication occur at the same 
time(25). 
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Figure 4 - Schematics for both vegetative and relaxed replications of mtDNA. From ref(25). 
 
Therefore, MGT must be able to deliver enough synthetic plasmid DNA to offset 
the number of mutated copies, in order to revert the dysfunction. Once enough copies 
have been delivered to offset the ratio of mutated mtDNA, the mitochondria may clonally 
expand the new plasmid, causing new mitochondria replicated during mitosis to lack 
enough copies of the mutated mtDNA for the dysfunction to remain.(26)  
For transfection to occur, several conditions must be met: the DNA delivery 
system must pass undetected through the immune system (in vivo); it must reach the 
targeted cells; it must be able to interact with the cell’s membrane, in order to be 
internalized, either by endocytosis or through direct translocation; once the system is 
able to get inside the cell it should have the ability to avoid lysosomal degradation, by 
performing an endosomal escape; lastly the delivery system should release the 
encapsulated DNA near the target organelle (Figure 5)(27). 
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Figure 5 - Schematic of the path a gene delivery system must go through for transfection to successfully occur. 
From ref(27). 
 
Direct translocation is an internalization process independent of both energy 
and proteins present in the cellular membrane, being mediated by the ability of the 
surfactant or surfactant/lipid mixture to interact and destabilize membranes with 
specific lipid composition(28). Endocytic pathways, however, are highly dependent on 
the proteins present on the membrane, relying somewhat less on the chemical 
compatibility of the transfection system’s chemical nature with biological membranes. 
The downside is that the system must be able to escape the endosome in order to 
free the DNA. Such is the case in clathrin and caveolae-mediated endocytosis(27).  
In the endocytic pathways it should be noted that the size of the transfection 
system is an important factor to consider, since the ideal size for internalization varies 
with the pathway (macropinocytosis being the pathway able to accommodate larger 
structures). If the complexes are too small, they might not be able to interact with 
enough membrane proteins to start the process; if too large, it might be impossible 
for the cell to proceed on their uptake. 
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1.1.4 Conventional vectors for transfection 
 
The simplest approach to gene delivery is direct DNA injection, but this method 
has the drawback of being to process only one cell at a time, making it unusable for most 
medical applications(29). Many other strategies for gene delivery have been created in 
the last years, from folded DNA boxes(30) to metallic nanoparticles(31), each with their own 
advantages and disadvantages.  
 
 
A common strategy when using nanoparticles is to adsorb the DNA at the 
particle’s surface(32) (Figure 6), thus allowing them to be more easily internalized by the 
cell(33). 
The vector that immediately stands out as an efficient way to transfect DNA into 
cells is the virus, since introducing genetic material into cells is the natural way for a virus 
to replicate – this causes naturally a high transfection efficiency. However, custom 
viruses have a high cost of production and require better safety standards due to their 
natural high mutability(34-35). 
On the other hand, lipid-based transfection systems have great potential for DNA 
transfection due to their versatility.(29) There is a myriad of different lipids, surfactants and 
combined lipid/surfactant system that can be used, allowing for greater refinement of 
transfection, depending on the types of cells and targets. Some lipids commonly used 
for transfection, due to their high efficiency and low cytotoxicity, are lipofectamine©(36), 
monolein(37) and DOPE(38).  
Lipid-based transfection systems work by encapsulating, adsorbing or otherwise 
securing DNA in self-assembled structures. These self-assemblies mimic the cell’s own 
Figure 6 - Representation of DNA chains adsorbed to a 
nanoparticle's surface. 
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chemical and physical structure, allowing them to be internalized along with DNA. 
However, lipids suitable for this application are expensive, so their synthetic alternatives, 
the surfactants, are a desired field of study. Like lipids, surfactants also have both and 
hydrophilic and hydrophobic region, but their chemical nature is very distinct, usually 
having smaller size and molar mass. The downside of surfactants is their typically low 
biocompatibility, increasing their cytotoxicity. To get the “best of both worlds”, surfactant-
based transfection systems usually have included in their composition some lipids to 
counter this effect, called the helper lipids(39). These mixed systems are usually referred 
to as lipoplexes. 
Helper lipids not only increase the biocompatibility of a surfactant-based system, 
but also can give those systems extra or augmented properties. An example of this is 
DOPE, which can be used to increase the efficiency of endosomal escape in transfection 
systems that use this route(28). 
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1.2 Lipids and Surfactants 
Surfactants are a class of molecules with a unique chemical structure, that 
confers them unusual properties. These molecules have a hydrophobic part (apolar; 
usually a long hydrocarbon chain) and a hydrophilic (polar) part, both important in 
defining the physicochemical behaviour of the whole molecule. Surfactants can be 
classified by several properties, usually: 
 By the polar head group charge, as anionic, cationic, zwitterionic and non-ionic; 
 By the polar head group chemical nature, as amines, carboxylates, amino acid 
derived, etc; 
 By the number of both apolar chains (single-chained, double-chained, etc.) and 
polar head groups (monomeric, dimeric, etc.); 
The combination of different polar head groups and hydrophobic chains in different levels 
of complexity allows an enormous variety of surfactants. (40-41) 
 
 
One may think that these molecules may be somewhat rare to find outside an 
applied chemical environment, but that is far from the truth. In reality surfactants are 
present not only in research and industrial processes, but in living systems aswell. Lipids 
are the building blocks of all cell membranes and play other different roles in nearly all 
of the organisms, from intracellular signalling(42) to preventing lungs from collapsing on 
themselves(43-44). 
 
  
Figure 7 -  Representation of a simple, one hydrophilic headgroup/one hydrophobic tail 
(left) and a more complex, one hydrophicilic headgroup/two hydrophobic tails (right) 
surfactants. 
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1.2.1 Surfactant properties 
 
Since surfactants have a dual nature in terms of polarity (they are both hydrophilic 
and hydrophobic) in separate zones of the molecule, some peculiar properties appear.  
 
 
While in solution, surfactants tend to concentrate more at the surface or interfaces 
of the solution than in the bulk due to the presence of the hydrophobic tail, as its contact 
with water molecules is not as favourable as the contact with air. Furthermore, the 
creation of an interface between two media of different polarities, such as water/air is 
also unfavourable, giving rise to an interfacial tension (i.e. excess Gibbs energy per unit 
area of surface) and an increase of the overall Gibbs energy of the system(27). This makes 
it thermodynamically favourable for the surfactant molecules to move to the interface in 
order to make the contact between the two more favourable and reducing the Gibbs 
energy. 
In the case of a water/air interface, the surfactant molecules gather on the surface 
and reduce the Gibbs free energy of the area of contact between the two media (Figure 
8). This reduces the energy per area unit that is necessary to keep the two phases 
separate, as the surfactant acts a stable link between them. Furthermore, the surfactant 
molecules intercalate with the water molecules at the surface (which are more 
structurally organized than in the bulk), making them lose cohesiveness among them(45), 
thus lowering the surface tension. 
 
  
Air 
Water 
Figure 8 -  Visual representation of the air/water interface and 
surfactant adsorption on it. 
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1.2.1.1 Surface tension 
 
Surface tension manifests itself as the differences between the Gibbs energies 
of molecules located at the surface and the bulk of a liquid. Due to this difference, the 
surface of the liquid has a tendency to reduce its area of contact with air. 
In the case of a liquid-air interface (a surface), different forces act on the surface’s 
molecules and bulk molecules (Figure 9). In the bulk, solvent molecules are completely 
surrounded by equal molecules and have forces pulling them in all directions 
simultaneously, with a resulting null net force. At the surface, however, molecules are 
not surrounded by the same number of molecules and the resulting net force pulls them 
inward into the solution (Figure 9). Additionally, the surface acquires an elastic-like 
behaviour due to this aspect. 
 
Figure 9 - Representation of forces acting on water molecules at the surface and in the bulk. From ref(46). 
This greater cohesiveness, between liquid-liquid molecules than liquid-air 
molecules, makes creation additional surface area energetically unfavourable. Due to 
these molecular aspects, the surface tends to reduce its area in order to reduce the 
unfavourable interactions.  
Surface tension can then be thermodynamically defined by the reversible work 
need to expand this surface area, as demonstrated in eq. [ 1 ], where γ is the surface 
tension, w the reversible work and ΔA the increase in total surface area. 
 Aw    [ 1 ] 
For a planar surface and constant pressure and temperature, surface tension can 
be defined in terms of Gibbs energy (eq. [ 2 ]). 
 
TpA
G
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  [ 2 ] 
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1.2.2. Self-Assembly 
 
As more and more surfactant is added into a solution, the surfactant adsorption 
at the surface starts to become thermodynamically unfavourable (this means the surface 
tension can’t be infinitely lowered). Since surfactant molecules cannot adsorb to the 
interface anymore the surfactant molecules start organizing themselves, in a process 
called self-assembly, in organized structures (Figure 10), in order to minimize the contact 
between the tails and the solvent, thus minimizing the hydrophobic effect. 
 
 
The concentration at which the surfactant molecules start self-assembling is 
called the critical aggregation concentration (cac). Once the critical micelle or 
aggregation concentration has been achieved in a solution, it will not change with the 
addition of more surfactant molecules. The extra molecules will form self-assembled 
structures, maintaining the solution’s unimer concentration constant. 
However, surfactants do not all organize in the same manner, with different 
molecules assembling in different types of structures, such as micelles and vesicles, 
among others. It should be noted that in many cases it is not only the nature of the 
molecule that defines the structure but also the concentration of said molecules. 
The type of structure a surfactant self-assembles into can be predicted to some 
extent by two distinct models, discussed below. 
 
  
Water 
Air 
Figure 10 - Representation of a surfactant solution at the cmc and 
formation of micelles. 
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1.2.2.1 Surfactant packing parameter 
 
The surfactant packing parameter associates the volumetric geometry of a 
molecule to the structures it is likely to self-assemble into, in a solution. This parameter 
is defined by the ratio between the actual volume occupied by the molecule, defined by 
the volume of the hydrocarbon chain (Vhc; Figure 11), and the theoretical volume it would 
occupy considering a cylindrical shape with the optimal area (ahg) of the polar headgroup 
and the length of the hydrocarbon chain (lhc), as seen in eq.[ 3 ]. 
 
hchg
hc
S
la
V
P   [ 3 ] 
 
Figure 11 - Visual representation of the volumes used for the calculation of the packing parameter Ps. From 
ref(47). 
 
It is considered that when Ps<1/3 (cone shaped molecule), surfactants will 
preferably assemble into spherical micelles, with cylindrical micelles arising at 
1/3<Ps<1/2 (truncated cone shape). At 1/2<Ps<1 the preferred structures are vesicles 
and flexible bilayers (as Ps approaches 1), with planar extended bilayers at Ps=1. Above 
Ps=1 surfactants will tend to form reverse spherical or reverse cylindrical micelles (Figure 
12). 
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Figure 12 - Visual representation of the relation between the surfactant packing parameter and the structure 
formed. Adapted from ref(27). 
It is difficult to calculate the value of ahg due to many variables that interfere with 
it (such as the presence of salts in the solution), but the values of Vhc and lhc can be 
estimated for simple surfactants by the formulae (eq. 2 and eq. 3) below, where nc is the 
number of carbons in the hydrocarbon chain: 
 
 
chc nnmV 0269.00274.0/
3   [ 4 ] 
 
 
 
chc nnml 127.0154.0/   
[ 5 ] 
1.2.2.2 Spontaneous curvature 
 
As an alternative to the surfactant packing parameter model, the spontaneous 
curvature model is especially useful for the description of different kinds of bilayer based 
structures, such as vesicles and planar bilayers. 
In this model, all structures are considered to be formed by surfactant films, with the 
structure formed defined by the curvature of the film. This can be described by the 
following equation (eq. 4), in which H0 is the spontaneous curvature, and R1 and R2 are 
the radii of curvature in perpendicular directions. 
 







21
0
11
2
1
RR
H  [ 6 ] 
Each radius, R, has an associated signal (positive or negative) related to the 
direction of a vector that defines it on the self-assembled structure. By convention the 
polar region is always taken as positive (Figure 13). 
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Figure 13 - Visual representation of the curvature in self-assembled structures and respective radii. From ref(47). 
 
A regular spherical micelle has two defined radii with a positive signal, giving it a 
spontaneous curvature of 1/R, while a planar bilayer film has a H0 of ≈ 0 (zero curvature) 
since both its radii are immeasurable (considered infinite). A reverse spherical micelle 
has H0 = -1/R, since its polar region is in the innermost part of the sphere. 
The spontaneous curvature adopted by a surfactant film is always the one that 
minimizes the Gibbs energy of the system. Unlike the packing parameter, which relates 
the shape of the final aggregate to the nature of the individual molecule, the spontaneous 
curvature refers more to the physical properties of the film as a whole. 
 
1.2.3 Structures 
 
While alone in a solution, each individual surfactant molecule is called an unimer, 
the basic unit of any self-assemblage. By order of complexity, the first and simplest self-
assembled structure that can be formed is the micelle. Micelles can have several shapes, 
depending on the surfactant concentration and packing parameter, among them 
spherical, elongated, cylindrical and worm-like shapes. In all these structures, the 
hydrocarbon chains are directed to the centre, reducing their contact with the aqueous 
media.  
In certain conditions, such as packing parameter > 1 or the presence of a high 
amount of a hydrophobic substance (such as an oil), reverse micelles can be formed, 
which have their hydrophobic tail turned outward. 
Next on the order of complexity are the vesicles (Figure 14). These usually 
spherical structures are formed by a curved bilayer of the surfactant, having an aqueous 
pool. This structure is much larger than regular micelles and have typically slower 
dynamics, but unimers in it still exchange with those in solution over time in dynamic 
equilibrium. The large aqueous pool is a particularity of this structure that makes it 
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especially useful for drug delivery, since it can contain and protect water-soluble 
molecules. 
 
 
Figure 14 - Cross-section representation of a liposome. From ref(48). 
 
Bilayers are composed of opposing layers of surfactants, with either the 
hydrocarbon tails or the headgroups in contact, depending on the polarity of the solvent. 
They can be categorized in 3 distinct morphologies, closed (vesicles), planar and 
bicontinuous.(49)  
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1.2.4 Gemini surfactants – Structure and properties 
 
Gemini surfactants are composed of two hydrophilic and two hydrophobic 
moieties, covalently linked to each other usually at the headgroup level via a unit that is 
called the spacer(2). 
 
Like conventional surfactants, gemini can have innumerable structural variations. 
They can be classified mainly by symmetry (symmetric if both monomers have identical 
headgroup and hydrocarbon tail, asymmetric if they do not), charge of the headgroups 
(neutral, cationic, anionic or catanionic), chemical nature of both the headgroups and 
spacer(50-51), length of the hydrocarbon chains, origin of the headgroups (amino-acid 
derived, sugar derived(52), among others).  
 
Gemini surfactants, despite their high synthesis costs, have several 
advantageous properties over conventional single-chained surfactants, such as a lower 
cmc, higher surface activity and higher structural versatility(27, 53). 
The higher surface activity and low cmc are especially sought after in several 
areas, industry among them, since it lowers the amount of compound needed in 
comparison to a conventional surfactant to achieve the same effect. This helps turn 
industrial processes more efficient(54) and less prone to contaminations, helping to 
prevent toxicity in medical and cosmetic applications(55). Some gemini are even reported 
to have an antimicrobial effect(54, 56-58). 
Figure 15 - Bis-quat gemini surfactant alkanediyl-α,ω-
bis(dodecydimethylammonium bromide). Spacer with variable length.  
Adapted from ref(2). 
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In recent years gemini of various chemical nature and structural configurations 
have been studied for their applications in gene and drug delivery due to their efficiency 
and low cytotoxicity(54, 59-60), especially those derived from amino-acids(23, 59). In this work 
we approach serine-derived gemini surfactants. 
 
 
1.2.4.1 Serine-based gemini surfactants 
 
In recent studies, gemini derived from several amino acids have shown to be 
even better than conventional surfactants, for medical applications due to their even 
lower cytotoxicity(61-63). 
These amino acid derivatives show higher biocompatibility, due their structural 
likeness to biological molecules. This allows them to readily interact with biological 
membranes, facilitating the delivery of drugs/DNA into the cell, either by fusion with the 
membranes or by a facilitated internalization.(60) 
 
Serine-based gemini were synthesized for the first time in 2012(61), comprising of 
two N-alkylated serine residues linked by a simple hydrocarbon chain spacer. 
 
  
Figure 16 - Example of a gemini surfactant molecule. Serine derived gemini with a spacer of 
twelve carbons and both hydrocarbon chains with twelve carbons. 
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 1.2.5 Compaction and transfection of DNA by surfactants 
 
The interaction of DNA with the surfactant of a gene delivery system is of 
paramount importance to determine its ability to form stable and usable forms of 
aggregates for use in transfection. 
The DNA molecule possesses multiple negative charges along its double helix 
due to the phosphate groups present in its structure. These negative charges allow 
cationic surfactants, and their self-assembled structures to interact with the DNA chain. 
Most surfactants used for this purpose are cationic, given that the opposite charge grants 
a much stronger electrostatic interaction. However, uncharged surfactants can also be 
employed, although the nature of interaction is different, since they interact by van der 
Waals and hydrophobic forces alone, which are generally weaker(64-65).  
 
The type of self-assembled structure present in solution before DNA 
complexation will greatly change the final conformation of supramolecular 
surfactant:DNA aggregates(66). For example, it was reported(67) that when DNA is added 
to existing micellar systems it tends to form compacted globular complexes, with chains 
of DNA connecting several of these globules (Figure 17). Furthermore, with vesicle-
forming gemini surfactants, it was seen that the addition of DNA caused a rearrangement 
of the system, forming inverted hexagonal structure, containing DNA(27, 67). This 
aggregation of DNA with self-assembled structures is often called DNA packing. For 
cationic surfactants, the structures of the surfactant:DNA complexes depends greatly on 
the charge ratio between the two, leading to different levels of packing. 
Mixtures of cationic and neutral surfactants are often used to balance the 
magnitude of the interaction with DNA, preventing either excessive DNA packing (which 
would difficult its later release inside the cell) or too loose or non-existent packing. 
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Figure 17 - Example of DNA packing in an environment with cationic spherical micelles, as reported using 
electron microscopy. From ref(68). 
 
Concerning gemini surfactants, the compaction of DNA might involve a chain 
effect, derived from the combined effect of hydrophobic and electrostatic interactions, 
promoting the interaction of additional surfactant molecules over time, as more 
molecules are present, starting from a small cluster(27). This process has an enthalpy 
gain, thus, being favoured by a low cmc(27, 69). 
It was found that the most efficient compaction was mediated by those with short 
spacers (n=2, n=3)(27, 70), which form disperse micelle-like aggregates of the two 
components.  
For transfection purposes it was found that generally, the transfection ability is 
higher, for lower spacer lengths, correlating to the area occupied by the surfactant head-
group(27). This might be explained by the fact that short spacer maintain the positive 
charge of the cationic head-groups, in a distance more favourable for interaction with the 
4.9Å spaced, negatively charged phosphate groups in DNA(27). Additionally, it is not 
possible to generalize further the influences of the chemical nature of the bond between 
headgroup and spacer(27).  
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1.3 Aim of this project 
 
Mitochondrial gene therapy techniques and protocols are becoming ever more 
popular due to their potential ability to treat otherwise incurable diseases and syndromes, 
such as the ones referred in chapter 1.1.1. Like all gene therapies, the treatment 
efficiency depends on the delivery system chosen. This system must able to both survive 
the biological environment (degradation, inactivation, etc.) and be able to safely deliver 
the genetic cargo to the inside of cells. Many strategies and types of delivery systems 
can be adopted for this purpose. In this project, the strategy followed is the use of 
surfactant and lipid-based colloidal DNA carriers, with the specific objective of targeting 
the mitochondria, inside cells.  
This project is part of a more global study of gemini surfactants, both conventional 
and amino-acid derived, and their transfection abilities, developed in the research groups 
of University of Porto and University of Coimbra(23, 59-61, 71-75). The studies that have 
already been published, present not only the advantages of gemini surfactants to their 
monomeric counterparts in terms of DNA compaction, transfection efficiency and 
cytotoxicity, but also the advantages of amino-acid derived regular and gemini 
surfactants in terms of biocompatibility. In this project, we assess the influence of varying 
length of the hydrocarbon chains (from twelve to eighteen carbons long) in serine derived 
cationic gemini surfactants, all with the same hydrocarbon spacer (twelve carbons long). 
 The development of this project can be divided in three major parts: (1) organic 
synthesis of the serine-derived gemini surfactants; (2) Physicochemical, interfacial and 
morphological characterization of the neat surfactants and their complexes with DNA 
and helper lipids; (3) biological studies of the transfection efficiency and cytotoxicity of 
the complexes, in vitro; (4) comparisons with previous studies.
  
 
 
 
Chapter 2: Materials and 
methods 
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2.1 Serine based gemini surfactants organic 
synthesis 
 
2.1.1 Reagents and preparative reactions 
 
With the synthetic pathway used, both the spacer and side chain carbons must 
be added to the serine derivative in their aldehyde and dialdehyde (for the spacer) forms. 
Due to the overall instability of these long chain aldehydes, they must be synthesized 
right before their use in the main synthesis. 
All the aldehydes variants were synthesized using the same reaction, the 
tetrapropylammonium perruthenate (TPAP) catalysed oxidation of their respective 
alcohol forms(76), which are available commercially. TPAP was used in a molar quantity 
equal to 5% of the reagent. 
 
 
 
 
 
 
 
 
 
  
Figure 18 - Representation of the reaction of oxidation of 1,12-dodecanediol to 1,12-dodecanedial. 
Figure 19 -  Representation of the reactions of oxidation to aldehydes of the several long chained alcohols 
used. 
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2.1.2 Synthetic pathway 
 
The synthesis pathway for the (nSer)2N12 gemini surfactants used in this work 
has two initial reductive amination reactions. Both aminations were processed under 
Argon inert atmosphere with sodium triacetoxyborohydride (NaBH(OAc)3) as the 
reducing agent.  
The first reaction is used to attach the variable length hydrocarbon chain onto a 
o-methylated (in the carboxyl group), o-terc-butyl protected (in the alcohol group) serine, 
creating (nSer) monomers. In the second reductive amination the monomers are chained 
together to each other and the twelve carbon long spacer, by carefully maintaining 
reaction stoichiometry to avoid excess formation of unwanted species. The resulting 
Figure 20 - General synthesis pathway for the several gemini surfactants produced. 
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product was then doubly methylated with methyl iodide (CH3I) on both ternary amine 
groups, turning them into quaternary ammonium groups, with iodide counter ions. Lastly, 
the terc-butyl group was removed with trifluoroacetic acid (TFA), exchanging the iodide 
counter ions for trifluoroacetate counter ions in the process. 
 
2.1.3 Purifications 
 
2.1.3.1 Column chromatography 
 
To ensure that a minimum of side products are present at the end of each reaction 
step, column chromatography was employed to purify the resultant mixture of each step 
and isolate the desired product. 
These purification steps in the middle of the synthesis chain prevent the formation 
of compounds that could be inextricable from the desired product at the final step, when 
the final product is fully formed. 
The columns used have an embedded ceramic filter at the bottom and were 
packed with a thin layer of sodium sulphate (Sigma Aldrich) followed by fine silica, the 
stationary phase in the system. The mobile phase, or eluent mixture, depends on the 
reaction step that was purified, due to the different polarity needs of each intermediate 
product. 
Figure 21 - Flash column chromatography 
schematic. From ref(1). 
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The method employed differs slightly from the regularly used process since it was 
done under artificial air pressure, with a small air pump at the top of the column, a flash 
column chromatography (Figure 21).  
 
After the column separation, the relevant fractions (assayed by Thin Layer 
Chromatography (TLC)) were combined and the solvent was removed using a rotary 
evaporator, readying the product for the following step. 
 
2.1.3.2 Nuclear magnetic resonance (NMR) 
 
Nuclear magnetic resonance is a technique that employs the ability of atomic 
nuclei to absorb and re-emit electromagnetic radiation when a magnetic field is present. 
Some atomic nuclei, such as 1H, 13C, 14N, 15N, 19F, among others, are magnetic 
because of their charge and because they behave as if spinning. This magnetic property 
allows them to interact with magnetic fields, in a manner similar to bar magnets. 
However, unlike bar magnets, the atomic nuclei do not always align themselves to the 
magnetic field, due to quantum restrictions; they can also oppose it. These two 
configurations of the atomic nuclei are of different energy, lower energy being the aligned 
configuration while the opposed configuration has a higher energy level (Figure 22). 
 
Figure 22 - Representation of the different configuration of atomic nuclei without and with the presence of a 
magnetic field Bo and the energy gap between the aligned and opposed configurations. Adapted from ref(77). 
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The energy difference between the two configurations is unique to the type of 
nucleus in a given magnetic field and can be translated to an electromagnetic frequency 
by the Bohr relationship (eq. [ 7 ]) 
 
 hvE   [ 7 ] 
 
As an example, the 1H nucleus has an energy difference (ΔE) of approximately 
6.6 x 10-26 J in a magnetic field of intensity 2.35 tesla (T); thus, the correspondent 
frequency is 100 MHz, on the radiofrequency band of the electromagnetic spectrum. If 
the field intensity changes, so does the energy difference, increasing proportionally to 
the magnetic field intensity – with a field strength of 7.0 T for example, the frequency of 
the energy difference would be 300 MHz (Figure 23). 
While in the magnetic field, if the nuclei are irradiated with the radiofrequency that 
matches the frequency of the energy difference they will undergo transitions from the 
aligned state to opposed and vice-versa, absorbing part of the radiofrequency 
transmission energy. This process is called resonance. 
The resonating frequency of these nuclei vary not only with the strength of the 
applied magnetic field (Figure 23), but also with the chemical environment they are in, 
such as the neighbouring nuclei in a molecule with different electron densities, which 
change their magnetic susceptibilities. The change in resonating frequency by the 
chemical environment is called a chemical shift and is usually expressed in ppm (parts 
per million), and represented by the greek letter δ.  
 
 
Figure 23 - Changes in the resonant frequency of 1H nuclei with the change of the magnetic field's strength. 
Adapted from ref(77). 
 
By measuring both the frequency at which the nucleus absorbs the 
radiofrequency signal and how much it absorbs, it is possible to build a spectrum that 
can be read to identify the nature of the nuclei (and their chemical neighbourhood via the 
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chemical shift) and the number of these nuclei in the molecule. It is possible then to 
reconstruct the structure of the entire molecules by these data alone. However, it may 
require more than one NMR analysis to do so in more complex molecules.(77) 
NMR spectra peaks can also be split in several components due to spin-spin 
coupling, which arises from the nuclei interference with each other because of their 
innate small magnetic field.  
In this work, 1H NMR was used to determine the structure and purity of the 
products in the intermediate steps of the synthesis, while the final product of each 
synthesis was analysed by four distinct techniques: 1H, 13C, COSY and HSQC, to ensure 
that the products are in good purity for the rest of the work. With the exception of the final 
NMR spectra, for which the product was dissolved in deuterated acetone or dimethyl 
sulfoxide, for the intermediary NMR spectra, the products were dissolved in deuterated 
methanol. 
  
2.1.3.1 NMR peak attributions 
 
The synthesis of the various gemini surfactants were carried out by the procedure 
previously described. 
The characterization of the intermediate and final products of the synthesis was 
carried out by 1H and 13C (final products only) NMR, presented in the supplementary 
information section.  
The NMR data for (12Ser)2N12 is not shown, since it coincides with data already 
reported in literature(71). 
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2.2 Surfactant characterization 
 
2.2.1 Tensiometry - Wilhelmy Plate Method 
 
There are several methods that can be employed to determine the surface tension 
of a liquid, using different physical properties and characteristics. These methods can be 
divided in three distinct categories: 
 Based on force: such as Wilhelmy Plate method, Du Noüy Ring method and 
capillary elevation method; 
 Based on pressure: such as maximum drop pressure method; 
 Based on shape: such as sessile drop method and pendant drop method. 
 
     The shape-based methods need low amounts of liquid to determine the surface 
tension and are able to achieve good precision, but are technically difficult to execute. 
They may require some correction of the experimental values obtained (the sessile drop 
method requires chromatic aberration corrections when a camera is used to determine 
the contact angle). 
Force-based methods are also in general very precise, but much simpler to 
execute, the downside being that they require expensive equipment (with the exception 
Figure 24 – DCAT11 tensiometer used for the 
surface tension measurements. 
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of the capillary elevation method). The Wilhelmy Plate method was used for all surface 
tension measurements in this work.  
In this method, the Wilhelmy plate is attached to a balance, and a vessel with the 
liquid to be measured is placed under it. The balance is zeroed and the vessel with the 
liquid is then elevated until the plate breaks the liquid’s surface. At this point, a meniscus 
forms around the length of the plate due to the surface tension, which exerts a downward 
force, pulling the plate (Figure 25). This force is measured by the balance and is used to 
calculate the surface tension by the following formula (eq. [ 8 ]). 
 
 


cos


plate
measured
L
Gm
 [ 8 ] 
 
Here, γ is the surface 
tension, mmeasured is the value 
measured by the balance, G is 
gravitational constant, Lplate is 
the plate’s perimeter and θ is 
the contact angle of the liquid 
with the plate. Since the plate 
is made of a rough platinum or 
platinum-iridium alloy, the 
contact angle θ=0°, thus being 
completely wetted by the liquid. The equation can then be simplified (eq. [ 9 ]). 
 
 
L
F
  [ 9 ] 
 
 
Experimental procedure 
 
For this work, a DCAT11 tensiometer from Dataphysics was used. This apparatus 
consists of a sealed chamber (to stop air drafts from affecting the measurement) with a 
motorized elevation platform of high precision (with an error of ±0.0001 mm) with a 
thermostatization module (fed from an external source, a thermostated bath from 
Julabo), and a high precision balance (±0.00001 g) on the top. 
Figure 25 - Wilhelmy Plate method theoretical schematic. 
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A glass vessel was used for the solution, previously washed with deionized water 
and ethanol, and dried in an oven at 100°C. The Wilhelmy plate was also washed with 
deionized water and ethanol, but dried in a butane flame. 
For all experiments the vessel was loaded with 25.0g of ultra-pure water 
(Millipore™) and the surface tension measured, to further assess the purity of the water. 
Surfactant solutions were prepared within 24 hours of the measurement with ultra-pure 
water and maintained overnight in an oven at 25°C.  
Aliquots of the surfactant solution under study were transferred to the vessel, 
using micropipettes (Gilson™). For each aliquot added the solution was magnetically 
agitated for 3 minutes, followed by 1 minute of rest. The plate was then immersed in the 
solution and left to stabilize for at least 5 minutes. 
Each curve obtained by this method contains 20 to 29 surface tension data points, 
each for an added aliquot. 
 
Figure 26 - Inner chamber of the DCAT11 tensiometer, with attached Wilhelmy plate, during a measurement. 
From the surface tension curves, one can gather relevant parameters, such as 
the surface tension of the dispersion at the cmc, the maximum surface excess 
concentration, Γmax (page 34) and the minimum surface area per molecule, aSmin (page 
34). 
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2.2.2.1 Calculating the cmc 
 
The surface tension obtained was plotted versus the natural logarithm of 
surfactant molal concentration.  
The critical micelle concentration (cmc) was determined by intersecting two linear 
regressions of two sets of data points, the first one being the set that contains the data 
points that form a regression with the highest slope and the second the set contains the 
data points at which the surface tension is stabilized (referred as the surface tension 
plateau), as graphically exemplified below (Figure 27). The concentration at this point of 
intersection yields the cmc. 
Figure 27 - Graphical example of the method used to calculate the cmc. 
 
  
cmc 
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2.2.2.2 Maximum surface excess concentration 
 
Surface excess concentration is the excess concentration of surfactant molecules 
adsorbed at the air-water interface, within the Gibbs ideal model and as defined by the 
Gibbs isotherm (eq. [ 10 ]). 
 
 
A
ni
i

  [ 10 ] 
 
This parameter was calculated by using the highest slope obtainable in the curve 
and applying it to eq. [ 11 ], where n is the number of chemical species considered; n=2 
for a partial counter-ion dissociation of the cationic surfactant, while n=3 is used for a full 
dissociation and the three species coexist. 
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nRT ln
1 
  [ 11 ] 
 
2.2.2.3 Minimum superficial molecular area 
 
This parameter is the minimum area a surfactant molecule occupies at the liquid’s 
surface. It is useful to determine if the surfactant in question has the hydrocarbon chain 
turned upwards or is lying longitudinally on the surface, among other diverse 
configurations, situations which have distinctive molecular areas occupied. It is 
calculated using Γmax and the Avogadro’s number (NA), as shown in following equation 
(eq. [ 12 ]). 
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1
min 
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a  [ 12 ] 
   
 
  
 A biophysical approach to mitochondrial gene therapy: 
gemini surfactant-based colloidal vectors  
 
35 
2.2.2 Dynamic Light Scattering 
 
The Dynamic Light Scattering (DLS) is a technique commonly used to determine 
the fluid dynamics and particle sizes of colloidal systems.  
DLS works by making a laser beam, typically originated from Helium-Neon or 
Argon excitation, hit the desired colloidal sample. The light from this beam is then 
scattered by the particles in suspension and detected at an angle, θ, to the incident beam 
(Figure 28). This scattered light has an intensity dependent on size and Brownian motion 
of particles, fluctuating over time(78-79).  
 
 
Figure 28 - Schematic of the dynamic light scattering measuring system. From ref(1). 
 
This scattered light is then analysed by an autocorrelator that generates a 
function g(τ), the auto-correlation function, enabling the determination of the diffusion 
coefficient D (eq. [ 13 ]) for monodisperse populations of particles. (79) 
 
 
2
)( Dqeg   [ 13 ] 
 
In this equation q represents the scattering vector, which depends (eq. [ 14 ]) on 
the solvent’s refractive index (n), the wavelength of incident light (λ0) and the scattering 
angle (θ).(79) 
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The diffusion coefficient D can then be used to calculate the hydrodynamic radius 
(RH) of the particles by the Einstein-stokes equation (eq. [ 15 ]), where KB is the 
Boltzmann constant, T is the absolute temperature, and η the solvent’s viscosity.(79) 
 
 
H
B
R
TK
D
6
  [ 15 ] 
 
However, for polidisperse particle populations which are more common, this 
calculation method cannot be used as it is. In polidisperse populations the diffusion 
coefficient must take in account various particle sizes and diffusion modes(78, 80). The 
most common way to obtain the diffusion coefficient in this case is to use the cumulants 
method, which uses a monoexponential correlogram fit to calculate the Z-average 
diameter and the polydispersity index (PDI), an estimate of the population 
polydispersity(81). 
This technique has the limitation of assuming that every particle it measures is 
spherical, which may induce error in some situations, such as the measurement of 
elongated aggregates and any other non-spherical particle. 
 
Experimental procedure 
 
The DLS measurements in this work were carried out in a Zetasizer Nano ZS 
machine, from Malvern Instruments. Each sample was prepared immediately before the 
measurement, directly inside the cuvette to prevent contaminations and reduce the time 
between preparation and measurement. They were measured at a scattering angle of 
173° known as backscatter analysis. Data was processed using Malvern’s Dispersion 
Technology Software (DTS). 
 
  
 A biophysical approach to mitochondrial gene therapy: 
gemini surfactant-based colloidal vectors  
 
37 
2.2.3 Zeta Potential 
 
Dispersed particles have a net charge that depends on the composition of said 
particle and affects the positioning of ions from the dispersion medium around them, 
forming an electrical double layer. The first and inner layer is called the Stern layer, where 
ions are strongly bound to the particle. The next layer is more diffuse with the ions more 
weakly bound. The interface between this outer layer and the dispersion medium is 
called the slipping plane(82). 
 
The zeta potential is the electric potential between the slipping plane of a 
dispersed particle and the dispersion medium, that is created when the particle 
experiences motion. It can be either negative or positive, depending on the particle’s 
charge(82-83). 
This potential can be used as a measure of stability of a colloidal dispersion, since 
a higher modulus of the zeta potential signifies a higher repulsive force between identical 
particles with the same charge, preventing aggregation(84).  
A modulus between 0 mV and 5 mV signifies that the particles will quickly 
aggregate, while moderate stability is only achieved from a modulus of 30 mV, with 
stability increasing as the modulus increases. This property can be measured by 
determining the electrophoretic mobility (velocity of a particle in an electrical field) of the 
particles, by the laser Doppler velocimetry. This is then calculated using the Henry’s 
equation (eq. [ 16 ]), where UE is the electrophoretic mobility, z is the zeta potential and 
f(ka) the Henry’s function. By the Smoluchowski approximation the Henry’s function has 
Figure 29 - Various layers of charges acquired by a particle and the 
corresponding interlayer interfaces. From ref(1). 
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a value of 1.5 for aqueous solutions, and by Hückel approximation a value of 1 for non 
aqueous solutions(82, 84). 
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Experimental procedure 
 
 
Zeta potential determinations were also made in the 
Zetasizer Nano ZS by Malvern instruments. Each sample 
was prepared immediately before each measurement. One 
milliliter of each sample was transferred to a U-shaped 
cuvette with electrodes from Malvern Instruments (Figure 
30) and left to reach thermal equilibrium inside the 
equipment for two minutes. Zeta potential was then 
measured at a scattering angle of 17°. 
Data was processed using Malvern’s Dispersion 
Technology Software (DTS). 
 
  
Figure 30 - U-shaped cuvette with 
electrodes used for zeta potential 
determination. 
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2.2.4 Light Microscopy 
 
 Bright field microscopy was used for the morphological analysis of the aggregates 
in this work. This type of microscopy involves direct observation of an amplified image of 
the samples, backlighted by visible light, outputted through a series of lenses. This 
amplified image has a high resolution and high contrast between the objects and 
background, allowing the resolution of more details. 
The image obtained by this type of microscopy cannot be amplified indefinitely, 
having a finite resolution defined by three major components: the quality of the lenses, 
the wavelength of the light source used and the aperture of the objective. 
The quality of the lenses depends on the structural quality and purity of the glass 
and the precision of the geometry (such as curvature) of the finished lens. 
The dependency of the resolution with the light’s wavelength and numerical aperture is 
given by the following equation (eq. [ 17 ]).  
 
 
NA
R
2

  [ 17 ] 
 
Where R is the resolution (in nm) and NA is the numerical aperture. 
Since the studied samples have very low 
contrast due to almost complete absence of colour, 
two techniques, derived from the use of polarized 
light were used to overcome this problem, as 
discussed further. 
This was done in an Olympus BX51 
microscope, linked to an Olympus C5060 digital 
camera. The samples were sealed between a slide 
and coverslip using a fast drying hydrophobic 
compound to prevent evaporation and 
contamination during the analysis.  
 
 
  
Figure 31 - Olympus BX51 optical 
microscope used in this work. 
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2.2.4.1 Polarized light microscopy 
 
 Regular polarized light microscopy allows portions of the sample which have 
anisotropic optical qualities to be detected, because of their birefringence. Birefringence 
exists due to fact that the sample has a refractive index dependent on the polarization 
and direction of propagation of light. This property is present in many materials and 
crystals under stress, but also on self-assembled surfactant structures, such as bilayers 
and some liquid crystals. 
This technique works by passing a beam of polarized light, obtained through a 
polarizing filter after the source, through the sample (Figure 32). This polarized light then 
passes through another filter before going into the microscope’s lenses. The second filter 
only allows light that was interfered with by the sample (acquiring a different polarization 
plane due to the varying refractive indexes). Birefringent samples modify the polarized 
light by turning it into two separate waves with perpendicular planes. 
 
 
Figure 32 - Schematic of the working of a polarized light microscopy system. From ref(85). 
  
 A biophysical approach to mitochondrial gene therapy: 
gemini surfactant-based colloidal vectors  
 
41 
2.2.4.2 Differential interference contrast microscopy 
 
 
 Differential interference contrast microscopy (DIC) uses a double beam of 
polarized light, created by the Normarski prism, to interact with the sample. These two 
beams are then recombined by the DIC prism immediately before the second filter. The 
two beams are separated by a small distance, allowing them to interact with the sample 
and to suffer interference in slightly different ways. Due to this, once the beams are 
recombined the image becomes slightly three-dimensional, increasing contrast with the 
background. 
 
  
Figure 33 - Comparison between images obtained by the DIC (a) and regular polarized light 
(b) techniques. It should be noted in (b) the blue zones that sign the presence of 
birefringence. Images from (18Ser)2N12 binary complexes. 
 
a 
b 
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2.3 Biological studies 
 
2.3.1 Cell Line and Culture Conditions 
 
The biological assays were performed in the immortal human epithelial cervical 
carcinoma (HeLa) cell line, derived from cervical cancer cells originally taken from a 
patient in 1951. 
The cell culture (Figure 34) was maintained at 37°C, in 5% CO2, in Dulbecco’s 
Modified Eagle’s medium-high glucose (DMEM-HG, Sigma Aldrich) supplemented with 
10% (v/v) heat inactivated fetal bovine serum (FBS) and 100 units of penicillin and 100 
µg of streptomycin per mL.  
Cells grown adherent in monolayers at 50–70% confluence were detached by 
treatment with 0.25% trypsin solution (Sigma Aldrich) and split every two or three days, 
Cell suspensions were diluted 1:1 with trypan blue and cells were counted using a 
haemocytometer. 
 
 
Figure 34 – Microscopy image from one of the HeLa cell cultures, used in this work. 
 
For the following experiments, cells  were seeded in 12-well plates (8x104 cells 
per well) 24 hours prior to transfection with the gemini-based complexes. 
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2.3.2 Preparation of gemini surfactant-based complexes 
 
Surfactant-based complexes were prepared using a GFP-encoding plasmid DNA 
(mtDNA), specifically expressed in mitochondria. 
The gemini surfactants comprised two amine series with different spacer lengths 
of 5 and 12 carbons, both with alkyl chain lengths of 12, 14, 16 and 18 carbons. 
For each gemini surfactant, aqueous solutions at a concentration of 0.5 mM were 
prepared and then filtered through 0.2 µm pore diameter filters (Schleicher and Schuell).  
Helper lipid dispersions were prepared using 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and cholesterol (Chol) (Avanti Polar Lipids) dissolved in 
chloroform, mixed at 2:1 molar ratio, and then dried under vacuum in a rotary evaporator. 
The dried lipid films were hydrated with HBS at pH 9.0, resulting in the formation of 
vesicles, at a final lipid concentration of 0.5 mM, which were then filtered through a 0.2 
µm pore diameter filter. 
Plain complexes, composed of gemini surfactant and plasmid DNA, were 
produced by mixing aliquots of mtDNA with the previously prepared gemini surfactant 
solutions, to achieve 3 distinct gemini surfactant/DNA (+/-) charge ratios: 8/1, 10/1 and 
12/1, following incubation at room temperature for 15 min to allow complex formation. 
Ternary complexes, composed of gemini surfactant, mtDNA and helper lipids 
(DOPE:Chol), were prepared by adding the HL dispersion to the plain complexes to 
achieve a 1:1 surfactant:HL molar ratio. 
All complexes were allowed to incubate for further 30 minutes at room 
temperature to allow full stabilization. 
 
2.3.3 Cell Transfection 
 
Binary gemini surfactant/mpDNA, or ternary gemini surfactant/mpDNA/HL 
complexes were added to each well (0.5 µg mtDNA per well) in the previously seeded 
12-well plates, in serum-free OptiMEM medium and left to incubate at 37°C and 5% CO2 
for 4 hours. After the transfection period, the medium containing the complexes was 
replaced by complete DMEM medium, and the cells were let to incubate for further 44 
hours. 
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2.3.4 Evaluation of mtDNA expression 
 
Transfection efficiency mediated by the gemini surfactant-based complexes was 
evaluated using flow cytometry to determine the percentage of cells expressing GFP. 
Flow cytometry allows for the simultaneous measurement and analysis of multiple 
physical characteristics of cells, including relative cell size, granularity and fluorescence 
intensity, as individual cells pass through a focused laser beam. 
Forty-eight hours after transfection, cells from each well were washed once with 
PBS buffer and detached with 0.25% trypsin solution (Sigma Aldrich) at 37°C and 5% 
CO2 for 10 minutes. Cells were further washed three times by centrifugation (200 g, 4°C, 
5 minutes) in ice-cold PBS, and immediately analysed by flow cytometry. 
Flow cytometry was performed in a FACScalibur flow cytometer (BD Biosciences) 
and data gathered by CellQuest software were processed using FlowJo software. Live 
cells were gated by forward/side scattering from a total of 10,000 events, which were 
further gated by GFP fluorescence, which determines transfection success. 
Transfection efficiency was determined as a percentage of cells expressing GFP 
from the total of viable cells (eq.[ 18 ]). 
 
 
100
cells  viableofNumber  
cells  expressing GFP ofNumber  
(%) efficiencyonTransfecti  [ 18 ] 
 
 
2.3.5 Evaluation of Cell Viability 
 
Cell viability was assessed in parallel with transfection efficiency, to correlate the 
cytotoxicity promoted by the gemini surfactant-based complexes with the length of the 
spacer and alkyl chain of the gemini surfactants.  
The test used to determine cell viability was a modified Alamar Blue assay(86). In 
this assay, resazurin (dark blue) is reduced to resorufin (pink) (Figure 35), which is highly 
fluorescent, by metabolically active cells. The redox capacity of the cells is a measure of 
their viability, thus being possible to assay cytotoxicity of compounds incubated with the 
cells by how much resazurin they reduce. 
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Figure 35 - Resazurin reduction reaction. From ref(1). 
After 48 h of incubation with the gemini complexes, the medium was replaced 
with 0.4 mL of 10% resazurin dye in complete DMEM medium and cells were let to 
incubate at 37°C in 5% CO2 for 45 minutes. After the allotted time, 180 µL of the 
supernatant were collected from each well and placed in a 96-well plate (Figure 36). The 
absorbance of the supernatant was measured at 570 nm and 600 nm in a SPECTRAmax 
PLUS 384 spectrophotometer (Molecular Devices). It should be noted that for the Alamar 
Blue assay one can also use the values of fluorescence, instead of absorbance. 
 
 
Figure 36 – Example of cell viability assay supernatants after 45 minutes of incubation, in a 96-well plate. The 
colour of the wells represents the cytotoxicity of the complexes; the more pink a supernatant in the well is, the 
less cytotoxic was the complex. 
 
Cell viability was calculated as a percentage of the control cells (nontreated), 
using the following equation (eq. [ 19 ]), where A570 and A600 are the absorbances of the 
samples and A’570 and A’600 are the absorbances of the control, at the respective 
wavelengths. 
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Chapter 3: Results and 
discussion 
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3.1 Synthesis yields 
 
All gemini surfactants were successfully synthesized in this work according to the 
procedure described in section 2.1, with the exception of (12Ser)2N12, which already 
existed in stock and was analysed for its purity. 
Table 1 - Full reaction yields for each of the synthesized gemini surfactants and the corresponding structures. 
Gemini Yield (%) 
 
(12Ser)2N12 --* 
 
(14Ser)2N12 5.5 
 
(16Ser)2N12 16.8 
 
(18Ser)2N12 8.6 
*Synthesis not realized in this project. Analysed by NMR before use. 
 
The synthesis yielded high purity products, even though column chromatography 
purification for the various products of this synthesis pathways was somewhat difficult to 
complete. The low yields obtained are expected and result of the high complexity of the 
synthesis process and the need for intermediate purification between each step 
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3.2 Interfacial and aggregation properties 
 
3.2.1 Determination of cmc 
 
Critical micelle concentration was determined by the Wilhelmy plate method, as 
described in section 2.2.1. Measurements were performed at both 25°C and 40°C to 
determine if temperature had a significant influence on the cmc calculated.  
The method of calculating the cmc from chapter 2.2.2.1 was applied to the 
following data sets (Figure 37 to Figure 40). 
 
Figure 37 - Data plots for the Whilhelmy plate surface tension experiments for the gemini (12Ser)2N12. 
Separated by temperature. 
 
Figure 38 - Data plots for the Whilhelmy plate surface tension experiments for the gemini (14Ser)2N12. 
Separated by temperature. 
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Figure 39 - Data plots for the Whilhelmy plate surface tension experiments for the gemini (16Ser)2N12. 
Separated by temperature. 
 
Figure 40 - Data plots for the Whilhelmy plate surface tension experiments for the gemini (18Ser)2N12. 
Separated by temperature. 
 
It is possible to observe that the various gemini have a different behaviour in 
solution, since the tensiometric curves have a distinct profile depending on the gemini 
and on the temperature. The temperature effect is more evident in Figure 37 and Figure 
38. 
Considering the graphs for the various gemini surfactants, one can observe that 
the curves for (14Ser)2N12 were the less reproducible ones, at both temperatures. 
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Table 2 summarizes the results of all measurements for the four gemini 
surfactants. 
 
Table 2 – Summary of data from surface tension studies of the entire (nSer)2N12 gemini series. Includes 
temperature, critical micelle concentration, surface tension at cmc, maximum excess superficial concentration 
and minimum molecular area, in order. 
Gemini θ /°C cmc /µmol.kg-1 γcmc /mN.m-1 
Γmax x 10-6 /mol.m-2 aSmin /nm2 
n=2 n=3 n=2 n=3 
(12Ser)2N12 
25 10.1 ± 1.3 33.88 ± 0.23 
2.10 1.40 0.791 1.187 
2.34 1.56 0.710 1.065 
2.27 1.51 0.732 1.097 
40 11.6* 33.86* 1.86 1.24 0.894 1.340 
(14Ser)2N12 
25 4.82 ± 0.68 35.28 ± 0.75 
4.32 2.88 0.385 0.577 
4.33 2.89 0.383 0.575 
3.95 2.63 0.421 0.631 
40 2.9* 33.84* 3.72 2.48 0.447 0.670 
(16Ser)2N12 
25 10.5* 33.24* 2.63 1.75 0.632 0.948 
40 10.8 ± 0.9 33.16 ± 0.17 
2.48 1.65 0.670 1.005 
2.56 1.71 0.649 0.973 
2.32 1.55 0.716 1.074 
(18Ser)2N12 
25 84.4* 35.27* 1.92 1.28 0.867 1.300 
40 70.4* 37.01* 1.83 1.22 0.907 1.360 
*Single measurement.  
 
All cmcs obtained are within the expected concentration range for this kind of 
compounds.  
From the (12Ser)2N12 to (14Ser)2N12 the usual surfactant hydrocarbon chain 
length/cmc trend seems to manifest, albeit in a reduced manner, with only a cmc 
decrease at about 50%. From there however, it inverts, with the cmc increasing with the 
length of the carbon chains.  
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3.2.2 Trends in cmc and comparison with previous studies 
 
Previous works on serine derived gemini surfactants have shown a decrease in 
the cmc as the hydrocarbon chain length increases(61)(Figure 41), which is a typical 
behaviour for surfactant systems. It can also be observed a decrease in the cmc with the 
increase in the spacer length, for both the conventional bis-quat gemini surfactant series 
and the (nSer)2N5 series (Figure 41). 
 
 
Figure 41 - Logarithm of cmc vs. hydrocarbon chain length for conventional gemini with a spacer of 5 carbons 
(Bis-quat n-5-n)(71, 87-88), serine derived gemini with a spacer of 5 carbons (Bis-quat (nSer)2N5)
(61), the conventional 
gemini with a 12 carbons spacer (Bis-quat 12-12-12)(71, 89) and the serine derived gemini series with a 12 carbons 
spacer studied in this work (Bis-quat (nSer)2N12). 
 
Differential Scanning Calorimetry (DSC) measurements were performed for the 
gemini surfactants synthesized, and no phase change was found between 10°C and 
90°C, at 3 mM concentration, thus Krafft temperature for the compounds is below the 
temperatures used for preparation of samples and posterior measurements.  
The critical micelle concentration is known for decreasing as the hydrocarbon 
chain of a surfactant increases in length. This trend is caused by the increased 
hydrophobic effect of the longer hydrocarbon chains(90). This relationship is kept in gemini 
surfactants, even amino-acid derived, with higher decreases in cmc, but surprisingly the 
trend is not observed in the whole (nSer)2N12series studied here. 
The trend seems to manifest at the beginning of the series, with the cmc 
decreasing from (12Ser)2N12 and (14Ser)2N12 (by a factor of about 2), but increases at 
(16Ser)2N12 (by a factor of about 2) and again at (18Ser)2N12 by a much larger factor 
of about 8. This break in the trend does not occur in similar series of serine derived 
gemini, like (nSer)2N5(61) (Figure 41), but the effect cannot be fully attributed to the 
Bis-quat (nSer)2N12 
Bis-quat (nSer)2N5 
Bis-quat n-12-n 
Bis-quat n-5-n 
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different spacer without further testing. This irregular variation could have its origin in the 
difficulty of measuring the surface tension by tensiometric methods due to these 
surfactant’s complex surface dynamics. These complex surface dynamics could possibly 
be caused by the long spacer containing in these gemini and its interference in the 
interaction between the positively charged headgroups. Thus, tensiometric studies were 
realized at higher temperature (40°C), which did not significantly change the cmc value, 
asserting the fiability of the results. 
Curiously, a similar variation of the trends was observed in a previous study(91), 
suggesting that the inversion in the decreasing cmc trend can be attributed to 
hydrophobic interactions between very long hydrocarbon chains present in the gemini, 
which would cause them to coil around each other. This “self-coiling”, as the author 
refers, would cause an increase in the energy needed to separate the coiled carbon 
chains so that the gemini could be part of an organized self-assembled structure, such 
as a micelle or liposome. The energy increase would hinder the adaptation of the system, 
thus increasing the number of surfactant molecules needed for the formation of 
structures, meaning an increase in the cmc. However, this hypothesis could not be 
verified without a more extensive study. 
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3.3 Biological studies 
 
3.3.1 Cell viability 
 
Gemini surfactants of both (nSer)2N12 and (nSer)2N5 series were tested for their 
cytotoxicity. 
In these assays both binary (without HL) and ternary (with HL) complexes were 
used, in order to determine if the helper lipid formulation would increase biocompatibility. 
As observed, addition of the DOPE:Chol helper lipids (identified by “HL” in the 
Figures) to binary complexes promoted a decrease of the cytotoxicity (Figure 42 and 
Figure 43). 
 
Figure 42 – HeLa cell viability 48 h after transfection with mtDNA complexes based on surfactants of the 
(nSer)2N12 gemini series, prepared in the presence or absence of the helper lipids DOPE:Chol (HL), as 
assessed by the Alamar blue assay. 
 
Considering the different charge ratios of gemini/DNA, the data show, that for 
binary complexes, the higher the ratio, the lower the cell viability, while the presence of 
the helper lipid did not result in significant effect in this trend. As it can also be observed, 
for each (+/-) charge ratio, both with and without HL, the cell viability increases with 
increasing hydrocarbon chain length of the gemini surfactant, except for binary 
complexes prepared from (14Ser)2N12 gemini surfactants (Figure 42), which seem to be 
less toxic than those with longer hydrocarbon chain length, at all charge ratios. 
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Figure 43 - HeLa cell viability 48 h after transfection with mtDNA complexes based on surfactants of the 
(nSer)2N5 gemini series, prepared in the presence or absence of the helper lipids DOPE:Chol (HL), as assessed 
by the Alamar blue assay. 
 
(nSer)2N5 series promoted a larger decrease in cell viability than the 
(nSer)2N12 series in the presence of HL, as opposed to the smaller decrease observed 
in the absence of HL.  
For ternary complexes, no clear trend can be observed, both in terms of charge 
ratio and hydrocarbon chain length, whereas binary complexes show a slightly 
decrease cell viability with the increase in charge ratio (Figure 43).  
It is also worth mentioning that the (16Ser)2N5-based complexes seem to 
promote less loss of cell viability over the charge ratio range evaluated, being more 
noticeable for cells transfected with the binary complexes. 
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3.3.2 Transfection efficiency 
Similar to the viability assay, for the transfection efficiency determination, the 
(nSer)2N5 series (Figure 45) was also tested for control purposes. 
 
 
Figure 44 -Transfection efficiency, determined in terms of percentage of HeLa cells transfected with mtDNA 
complexes based on gemini surfactants of the (nSer)2N12 gemini series, prepared in the presence or absence 
of the helper lipids DOPE:Chol (HL), as assessed by flow cytometry. 
 
The most striking feature in this data set is the very low transfection efficiency 
obtained with the complexes containing HL. The (14Ser)2N12 complexes are outside this 
trend, especially at the highest charge ratio, having a much larger transfection efficiency 
than the complexes formed by other gemini surfactants. However, its transfection 
efficiency is still low.  
This low efficiency may be related with the potential “protective” effect conferred 
by the helper lipids, which is reflected in the high viability of cells transfected with the 
ternary complexes (Figure 41). In fact, if the helper lipids contribute to decrease the 
interaction between the complexes and the surface of the cell membranes, the 
predictable outcome is a lower cytotoxicity, but also a lower internalization and efficiency 
of the complexes. Further studies are necessary to disclose this possibility. 
For binary complexes, the transfection efficiency increases with the increase of 
the (+/-) charge ratio, although this trend is less noticeable for the (14Ser)2N12–based 
complexes. (12Ser)2N12 and (16Ser)2N12 seem to be the most efficient transfection 
compounds, which is more notorious for complexes prepared at higher charge ratios. 
Since the evaluation of transfection excludes non-viable cells, efficiently 
transfected cells correspond to a small percentage of the whole cell population. 
Additionally, for a safe administration in an in vivo application, more than 20-30% 
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reduction in cell viability, caused by unspecific toxic effects of the transfection process, 
is undesirable and pose a risk to the patient.  
 
Figure 45 - Transfection efficiency, determined in terms of percentage of HeLa cells transfected with mtDNA 
complexes based on gemini surfactants of the (nSer)2N5 gemini series, prepared in the presence or absence of 
the helper lipids DOPE:Chol (HL), as assessed by flow cytometry. 
 
Complexes prepared with the (nSer)2N5 gemini surfactants present an overall 
lower transfection efficiency than those prepared with the (nSer)2N12 gemini surfactant 
series. The nearly null transfection efficiency observed with the 12 carbon spacer is 
maintained in this series, for complexes with HL, with the exception of the (12Ser)2N5 
gemini surfactant, which, for the highest (+/-) charge ratio tested, mediates transfection 
in 20% of the cells. 
In the absence of HL, a decrease of the transfection efficiency was observed with 
the increase of the hydrocarbon chain length (particularly at the (+/-) charge ratio of 12/1). 
However, the transfection efficiency increased markedly when the hydrocarbon chain 
length reached 18 carbons, being more than double the efficiency, when compared to a 
chain length of 16 carbons.  
Overall, the transfection efficiency for both series is relatively low. The gemini 
surfactants able to mediate the highest levels of transfection with reasonable efficiencies 
being those prepared from (18Ser)2N5 (Figure 45), (12Ser)2N12 and (16Ser)2N12 
(Figure 44). However, these gemini surfactant-based formulations were also those that 
promoted extensive loss of cell viability (Figure 42 and Figure 43). 
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3.3.3 Transfection efficiency vs. cellular viability 
 
 
 
In the graphs in Figure 46 one can observe that the (nSer)2N5 gemini series has 
a lower dispersion of cellular viability values across the entire sample spectrum (Figure 
46 b) than the (nSer)2N12 series. This series with the 5 carbon spacer also has the 2 
data points with the highest transfection/viability ratio of both series (8/1 and 12/1 
(18Ser)2N5). 
  
Figure 46 - Transfection efficiency VS Cellular viability for both series of gemini surfactants, (nSer)2N12 (a) and (nSer)2N5 
(b), for all three gemini:DNA charge ratios considered, with and without HL. 
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Data points from the (nSer)2N12 series are much less clustered (Figure 46 a), 
suggesting more different behaviours between each surfactant of the series. However, it 
is in this series that the highest transfection efficiency (12/1 (12Ser)2N12) and highest 
cellular viability (12/1 (18ser)2N12 HL) are achieved. 
In both series the data points of the samples containing helper lipids are more 
clustered together than those without, suggesting that the presence of HL somewhat 
masks the intrinsic properties of each surfactant. 
 
 
3.3.4 Comparison with previous studies 
 
Previous studies have been performed for the (nSer)2N5 gemini series, up to a 
gemini:DNA charge ratio of 8/1, showing several trends.  
In first place there is a decrease in cellular viability with the growth of the hydrocarbon 
chains length and the increase in charge ratio(59), while there is an increase in the 
transfection efficiency with the growth of the hydrocarbon chains length and the increase 
in charge ratio(59). 
It is also reported an increased transfection efficiency in complexes, for most of the 
charge ratios, containing HL(59-60) than the charge ratios studied in this work; 
This suggests a high dependence between gemini:DNA charge ratio and 
transfection, with lower charge/ratios being more beneficial for this series. 
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3.4 Lipoplex characterization 
 
3.4.1 Size stability studies 
 
Due to the detection of visible aggregation in preliminary samples, the size 
stability over time (1.5 hours) was evaluated, using gemini samples with a Gemini/DNA 
charge ratio of 12/1 without helper lipids, both at 25°C (Figure 47) and 40°C (Figure 48), 
and with helper lipids at 25°C (Figure 49). 
 
 
 
Figure 47 - Plot of the aggregate's size (Z-average) over time at 25°C, for the entire (nSer)2N12 gemini series at 
the Gemini/DNA charge ratio of 12/1. 
 
 
Figure 48 - Plot of the aggregate's size (Z-average) over time at 40°C, for the entire (nSer)2N12 gemini series at 
the Gemini/DNA charge ratio of 12/1. 
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In the absence of helper lipids, (16Ser)2N12 showed to be stable during the entire 
experiment, averaging a size of 194nm at 25°C and 261nm at 40°C. At 25°C, 
(12Ser)2N12 and (14Ser)2N12 increased in size over time but reached a plateau at about 
50 minutes, after which the size did not vary significantly. For (18Ser)2N12 the behaviour 
was different, since size did not stop increasing until the end of the experiment. At 40°C, 
no plateau was reached for any of the samples, with the exception of the stable 
(16Ser)2N12. 
 
 
Figure 49 - Plot of the aggregate's size (Z-average) over time at 25°C with helper lipids present, for the entire 
(nSer)2N12 gemini series at the Gemini/DNA charge ratio of 12/1. 
 
In the presence of helper lipids at 25°C, the behaviour of the samples changes 
dramatically. During the first 20 minutes, the lipoplex size is unstable, with a sharp 
increase followed by a decrease for the (12Ser)2N12 and (16Ser)2N12. The other two 
systems, however, showed to be more stable, with only a slight decrease followed by an 
even smaller increase in size.  
It is also noteworthy that the (12Ser)2N12 and (16Ser)2N12 ternary complexes 
show higher size fluctuations in the stable plateau than the other two. Curiously, the four 
ternary complexes seem to stabilize at two distinct sizes, hovering 1000 nm and 2000 
nm, without a dependence on the hydrocarbon chains length. 
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3.4.2 Particle size and Zeta potential 
 
All measurements were performed in accordance with the previously described 
method, with each sample being prepared immediately prior to the DLS and zeta 
potential analysis procedure. 
Table 3 - Size measured by DLS and zeta potential of (nSer)2N12 gemini series, both with and without helper 
lipids. 
Gemini 
Gemini:DNA 
charge ratio 
Without Helper Lipids 25°C With Helper Lipids 25°C 
Size (nm) Zeta potential (mV) Size (nm) Zeta potential (mV) 
(12Ser)2N12 
8/1 403 ± 49 30,5 ± 1,8 2753 ± 309 -35,1 ± 0,6 
10/1 536 ± 45 31,3 ± 1,2 1950 ± 107 -35,6 ± 1,1 
12/1 783 ± 72 30,9 ± 1,2 2959 ± 334 -43,1 ± 0,9 
(14Ser)2N12 
8/1 1401 ± 310 24,4 ± 1,6 871 ± 66 -37,7 ± 1,4 
10/1 1317 ± 248 23,7 ± 2,1 1236 ± 125 -35,5 ± 1,6 
12/1 1394 ± 215 23,4 ± 1,5 1232 ± 195 -42,6 ± 1,3 
(16Ser)2N12 
8/1 131 ± 1 32,5 ± 0,7 2857 ± 383 -33,6 ± 0,9 
10/1 137 ± 2 29,7 ± 0,6 2637 ± 360 -34,3 ± 2,7 
12/1 194 ± 1 33,4 ± 0,7 2633 ± 515 -47,6 ± 1,7 
(18Ser)2N12 
8/1 1397 ± 365 22,3 ± 1,5 730 ± 71 -26,8 ± 0,5 
10/1 1380 ± 391 23 ± 1,4 1275 ± 149 -30,1 ± 0,7 
12/1 1216 ± 305 20,9 ± 1,9 969 ± 119 -39,8 ± 0,6 
 
Starting by comparing the size of the complexes, it is noticeable that the ternary 
complexes (gemini/DNA/HL) containing (12Ser)2N12 and (16Ser)2N12 have a 
significantly larger size than their binary (gemini/DNA) counterparts. Among both the 
ternary and binary complexes, two charge ratio/size trends can be observed, both on the 
binary complexes of (12Ser)2N12 and (16Ser)2N12. Among all binary complexes, the 
most notorious for its size is the (16Ser)2N12 binary complex since it is of a much smaller 
size at all charge ratios. 
For binary complexes, we can observe that the zeta potential is always positive, 
while for ternary complexes the zeta potential values invert to a negative potential, with 
a higher modulus. (14Ser)2N12 and (18Ser)2N12 binary complexes have a slightly 
smaller zeta potential than the rest of the gemini series, but the ternary complexes do 
not show that difference. 
  
 A biophysical approach to mitochondrial gene therapy: 
gemini surfactant-based colloidal vectors  
 
62 
3.4.3 Morphology 
 
Visual comparisons between the various gemini/DNA charge ratios were carried 
out, but no distinct differences were found. Therefore, all images shown below belong to 
complexes of gemini/DNA (binary) and gemini/DNA/HL (ternary) with a charge ratio of 
12/1. 
Overall, there does not seem to exist a correlation between the shape and size 
of the visible structures and the hydrocarbon chain length of the gemini. However, the 
ternary complexes seemed to aggregate less in dense structures, and formed instead 
more numerous but smaller clusters. 
 
 
(12Ser)2N12 
gemini/DNA  
b 
c 
a 
Figure 50 - (12Ser)2N12 binary complexes images obtained under DIC (a and c) and polarized light (b). 
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gemini/DNA/HL 
 
For the (12Ser)2N12 binary complexes we could observe very large dense 
particles with some birefringence (Figure 50 a and b) and some less dense particles 
(Figure 50 c), seemingly formed by the same type of structures. These structures have 
a higher size than what was measured by DLS for the same complex. In the presence of 
helper lipids (ternary complexes), a bigger number of smaller aggregates is found, with 
size more similar to the values obtained by DLS (Figure 51). In both cases no neat 
organized structure such as bylayer structures could be identified. 
 
(14Ser)2N12 
gemini/DNA 
 
  
a b 
Figure 51 – (12Ser)2N12 ternary complexes under DIC. 
b a 
Figure 52 - (14Ser)2N12 binary complexes under DIC (a) and polarized light (b). 
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gemini/DNA/HL 
 
In the images for the (14Ser)2N12 binary complexes, we can observe less dense 
clusters of the same granular texture as seen before in (12Ser)2N12, with detectable 
birefringence. In ternary complexes, these granular textures disappeared, giving rise to 
smaller less packed structures, still maintaining a degree of birefringence (Figure 53). 
Like before, no neat organized structures could be identified. 
 
(16Ser)2N12 
gemini/DNA 
 
  
b a 
Figure 53 - (14Ser)2N12 ternary complexes under DIC (a) and polarized light (b). 
b a 
Figure 54 - (16Ser)2N12 binary complexes under DIC. Aggregate circled in red (a). 
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gemini/DNA/HL 
 
 
 
The binary complexes of (16Ser)2N12 are different than the rest, with only one 
possible structure found in the entire slide preparation (Figure 54 a, circled in red). This 
is in accordance to DLS data obtained previously, since the particles measured have a 
sizer lower than the resolution limit of the microscope used. In the ternary complexes of 
this gemini only little more could be found, exhibiting birefringence (Figure 55). 
 
 
(18Ser)2N12 
gemini/DNA 
  
a b 
Figure 55 - (16Ser)2N12 ternary complexes under DIC (a) and polarized light (b). 
a b 
Figure 56 - (18Ser)2N12 binary complexes under DIC (a) and polarized light (b). 
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gemini/DNA/HL 
 
Lastly, the (18Ser)2N12 binary complexes form large amorphous birefringent 
aggregates like the ones in (12Ser)2N12 and (14Ser)2N12 binary complexes (Figure 56). 
The ternary complexes of this gemini were difficult to detect, being of much smaller size 
(Figure 57 a). In the preparation slide, some evidences of phase separation were also 
found (Figure 57 b). 
 
Helper Lipids 
 
 
The helper lipid dispersion was also analysed under DIC microscopy, and 
multivesicular liposomes formed by them could be easily detected (Figure 58), as 
expected from this preparation. 
a b 
Figure 57 - (18Ser)2N12 ternary complexes under DIC. 
a b 
Figure 58 - DOPE:Chol helper lipid dispersion under DIC. 
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3.4.4 Trends in lipoplex properties and comparison with previous 
studies 
 
 
Previous studies on the (nSer)2N5 series have also shown an inversion in zeta 
potential with the addition of DOPE:Chol helper lipid system, especially at high 
hydrocarbon chain lengths and increased gemini:DNA charge ratios(59). 
This inversion did not happen in a similar study, in which the complex preparation was 
slightly different (for the (12Ser)2N12 gemini)(72). Within the same report, the (12Ser)2N12 
zeta potential agrees with the results in this work, at the measured charge ratios. 
However, there are some discrepancies with the DLS measured size of the aggregates 
with this gemini surfactants. 
Similar to the cmc determination results, the stability of aggregates size over time, 
both with and without helper lipids, showed unusual and curious tendencies. Without HL, 
only (16Ser)2N12 is stable over the entire timeframe studied, even though this complex 
has similar zeta potential values to the rest of the binary complexes (Table 3). Thus, this 
rapid growth of the other aggregates is most likely not due to the zeta potential 
parameter. Furthermore, the observed zeta potential values of the binary complexes 
should confer moderate stability in time, which is not observed. This difference between 
(16Ser)2N12 and the rest is visible in the microscopy results, being nearly impossible to 
find a (16Ser)2N12 aggregate (Figure 54) by the microscopy techniques used, due to 
resolution limits of the equipment. 
It is interesting to note that the binary complexes that aggregate to a high size do 
not do so in a linear fashion for the entirety of the measurement. They tend to have a 
more haphazard aggregation from the 40-45 minutes onward, at both temperatures 
(Figure 47 and Figure 48). 
With the presence of helper lipids (ternary complexes), the complexes’ behaviour 
changes dramatically. Their size is only unstable at the beginning of the measurement, 
stabilizing at a certain size from the 20-25 minutes mark (Figure 49). The much lower 
size of the (16Ser)2N12 binary complex is not noted here, with the behaviour of the 
ternary complex being much more similar to the rest.  
The inversion in zeta potential with the addition of HL is not expected, but as 
referred before it may be a result of the complexes’ preparation method. A possible 
explanation is that in the preformed gemini:DNA complexes both components are 
strongly bound, and cannot be rearranged as the HL lipid is added. Thus, the HL vesicles 
adsorb at the binary complexes surface, forming bigger structures with a negative zeta 
potential, coming from the contribution of DOPE. 
 A biophysical approach to mitochondrial gene therapy: 
gemini surfactant-based colloidal vectors  
 
68 
 The zeta potential of ternary complexes is also quite higher in modulus (Table 3) 
than those of binary complexes, granting them less tendency to aggregate. This is a 
visible effect in the microscopy pictures, as the ternary complexes form much smaller 
and fewer amorphous aggregates, the exception being (16Ser)2N12. 
 
3.5 Effects of lipoplex properties on biological 
activity 
 
 From the biological assays’ data for the (nSer)2N12 gemini surfactant series a 
trend arises for the complexes without helper lipids (binary). The higher the cellular 
viability, the lower the transfection efficiency. While the two parameters seem to be 
correlated, it is not possible to say with certainty that high viability is due to low 
transfection efficiencies. 
 When comparing the results from biological assays to the results from lipoplex 
characterization, no correlation between complex size and transfection efficiency/cellular 
viability is evident. However, there is some correlation between transfection efficiency 
and zeta potential – the binary complexes with highest transfection efficiencies are those 
containing the (12Ser)2N12 and (16Ser)2N12, which have a zeta potential rounding +31 
mV for both complexes at all charge ratios, while those with lower transfection (among 
binary complexes), containing (14Ser)2N12 and (18Ser)2N12 have a zeta potential 
rounding +23 mV.  
Ternary complexes have a high modulus negative zeta potential. Cellular 
membranes have a negative surface potential by themselves, thus, the more negative 
zeta potential a complex has, the more difficult it is for it to interact with the negatively 
charged cellular membrane (and consequently the mitochondria), due to electrostatic 
repulsions. Furthermore, the effect of the highly negative zeta potential in ternary 
complexes is also evident in microscopy results, as the macro-aggregates observed are 
smaller than their binary complexes counterparts. 
Although it is not observed in the biological experiments data, it was expected, 
considering results obtained from DLS, for binary complexes of (16Ser)2N12 to have 
better transfection efficiency due to their smaller size, which is ideal for cellular 
internalization via endocytosis.  
Taking into account the above considerations, a probable hypothesis is that 
transfection with (12Ser)2N12, (14Ser)2N12 and (18Ser)2N12 complexes occurs via 
fusion of these complexes with the cellular membranes, which could also explain the 
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relatively high cytotoxicity observed and the reasonable transfection even with very high 
complex sizes (such as were determined by DLS). Thus, gemini surfactants alone in the 
membrane would cause a disruptive effect on the membrane, untempered by the 
presence of helper lipids. The stable small size of (16Ser)2N12 binary complexes would 
suggest its internalization via normal endocytic pathways. 
 Further studies with internalization pathway inhibitors are required to 
determine the method of DNA internalization into cells with the complexes studied in this 
project. 
  
 
 
 
Chapter 4: Conclusions 
and future prospects 
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The physicochemical and biological studies carried out in this work are of great 
relevance for the development of ever more efficient gemini surfactant-based gene 
delivery systems, which rely greatly on the molecular properties of the DNA-complexing 
molecules. 
 It was found that the (nSer)2N12 gemini compounds possess a much lower critical 
micelle concentration than similar compounds with shorter alky spacers and the 
conventional bis-quat 12-12-12 gemini surfactants. The change in cmc with the length of 
the hydrocarbon chains presents an unusual and interesting trend, which warrants 
further study of serine-derived gemini, with hydrocarbon chains longer than 18 carbons. 
 The prepared binary (gemini/DNA) and ternary (gemini/DNA/helper lipids) 
complexes show distinct biological properties, with binary complexes having moderate 
transfection and relatively high cytotoxicity, while ternary complexes having little to no 
transfection ability, but barely showing cytotoxicity. These biological activities seem to 
be correlated both with the length of the hydrocarbon chain in a non-linear fashion and 
the gemini:DNA (+/-) charge ratio of the complexes, with transfection and cytotoxicity 
increasing with the increase in charge ratio. The higher cytotoxicity seems to be 
correlated with the increase in transfection, but further studies are required to prove the 
causal link. The values obtained in biological studies, especially the difference between 
binary and ternary complexes can in part be explained by the size and zeta potential 
values measured. 
As concerning future perspectives, further studies of internalization pathways and 
complex-membrane interactions (such as Fluorescence Resonance Energy Transfer 
(FRET) studies) will be required to further insight on the interactions of these gemini and 
their DNA complexes with living cells. 
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Dimethyl (2S,17S)-Bis(tert-butyloxymethyl)-3,16-ditetradecyl-3,16-di-azaoctadecane-1,18-dioate 
 
1H NMR (CDCl3, 400 MHz): δ 3.70 (t, 2H, J = 7.4 Hz, 2 x –CH(H)-OtBu); 3.68 (s, 6H, 2 x -OCH3); 3.54-3.42 (m, 4H, 2 x 
–CH(H)OH + 2 x -CH); 2.58 and 2.50 (dt, 4H, J = 14.9, 7.4 Hz and m, 4H, N-CH2-(CH2)10-CH2-N and –N-CH2-C13H27), 
1.48-1.34 (m, 8H, 2 x  -CH2-CH2-N-CH2-CH2-C12H25); 1.30 (bs, 60H, -(CH2)11- + -N-(CH2)2-(CH2)8-(CH2)2-N-); 1.16 
(18H, 2 x –C(CH3)3); 0.88 (t, 6H, J = 7.0 Hz, 2 x -CH3). 
 
Suppl. Info. 1 - 1H NMR spectra for dimethyl (2S,17S)-Bis(tert-butyloxymethyl)-3,16-ditetradecyl-3,16-di-
azaoctadecane-1,18-dioate. Intermediate product.  
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Dodecamethylenebis{[(2-tert-butyloxy-1-methoxycarbonyl)ethyl]-(methyl) (tetradecyl) ammonium} diiodide  
 
1H NMR (CDCl3, 400 MHz): δ 5.26-5.10 (m, 2 H, 2 x -CH); 4.24-4.02 (m, 4H,  
2 x -CH2O
tBu); 3.90-3.50 (m, 8H, 2 x –CH2-N
+(CH3)-CH2-C13H27); 3.82 and 3.81 (2 x s, 6H, 2 x –OCH3); 3.45 (bs, 6H, -
N+(CH3)-); 1.96-1.66 (m, 8H, -CH2-CH2-N
+(CH3)-CH2-CH2-C12H25); 1.50-1.20 (m + bs, 60H, -(CH2)11- + -N
+-(CH2)2-(CH2)8-
(CH2)2-N
+-); 0.85 (t, 6H, J = 6.8 Hz, 2 x -CH3).  
 
Suppl. Info. 2 - 1H NMR spectra for dodecamethylenebis{[(2-tert-butyloxy-1-methoxycarbonyl)ethyl]-
(methyl)(tetradecyl) ammonium} diiodide. Intermediate product.  
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Dodecamethylene-\ bis{[(2-hydroxy-1-methoxycarbonyl)ethyl](methyl)(tetradecyl)ammonium} 
Bis(trifluoroacetate) 
 
1H NMR (Acetone, 400 MHz): δ 4.78-4.72 (m, 2 H, 2 x -CH); 4.44-4.35 (m, 2H,  
-CH2OH); 4.35-4.26 (m, 2H, -CH2OH); 3.88 and 3.84 (2 x bs, 12H, 2 x –OCH3); 3.83-3.64 (m, 8H, 2 x –CH2-N
+(CH3)-CH2-
C13H27)  3.49, 3.47, 3.46, 3.45 and 3.40 (5 x bs, 6H, -N+(CH3)-); 2.00-1.73 (m, 8H, -CH2-CH2-N
+(CH3)-CH2-CH2-C12H25); 
1.38 and 1.28 (bs, 60H, -(CH2)11- + -N
+-(CH2)2-(CH2)8-(CH2)2-N
+-); 0.88 (t, 6H, J = 6.4 Hz, 2 x -CH3).  
 
 
Suppl. Info. 3 - 1H NMR spectra for dodecamethylene bis{[(2-hydroxy-1-methoxycarbonyl)ethyl] (methyl) 
(tetradecyl)ammonium} Bis(trifluoroacetate). Final product - (14Ser)2N12. 
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13C NMR (Acetone, 100 MHz): δ 168.7 (C=O); 74.3 and 74.2(5) (-CH); 63.9, 63.7, 63.6 (-CH2-N
+-CH2-C13H27); 60.5 and 
59.7 (-CH2OH); 54.6 (-OCH3); 48.9 and 48.8 (-N
+(CH3)), [33.6, 31.5-30.0 and 27.98 (N+(CH3)-CH2-(CH2)12-CH3)], 24.3 and 
23.9(-N+-CH2-(CH2)8-N
+),15.3 (-CH3). 
 
 
Suppl. Info. 4 -13C NMR spectra for dodecamethylene bis{[(2-hydroxy-1-methoxycarbonyl)ethyl] (methyl) 
(tetradecyl)ammonium} Bis(trifluoroacetate). Final product  - (14Ser)2N12. 
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Dimethyl (2S,17S)-Bis(tert-butyloxymethyl)-3,16-dihexadecyl-3,16-di-azaoctadecane-1,18-dioate 
 
1H NMR (CDCl3, 400 MHz): δ 3.71 (t, 2H, J = 7.6 Hz, 2 x –CH(H)-O
tBu); 3.71 (s, 6H, 2 x  
-OCH3); 3.57-3.45 (m, 4H, 2 x –CH(H)OH + 2 x -CH); 2.65-2.40 (2 m, 8H,  
N-CH2-(CH2)10-CH2-N and –N-CH2-C15H31), 1.50-1.37 (m, 8H, 2 x  -CH2-CH2-N-CH2-CH2-C14H29); 1.27 (bs, 68H, -(CH2)13- 
+ -N-(CH2)2-(CH2)8-(CH2)2-N-); 1.18 (18H, 2 x –C(CH3)3); 0.90 (t, 6H, J = 6.8 Hz, 2 x -CH3).  
 
 
Suppl. Info. 5 - 1H NMR spectra for dimethyl (2S,17S)-Bis(tert-butyloxymethyl)-3,16-dihexadecyl-3,16-di-
azaoctadecane-1,18-dioate). Intermediate product. 
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84 
Dodecamethylenebis{[(2-tert-butyloxy-1-methoxycarbonyl)ethyl]-(hexadecyl) (methyl)  ammonium} diiodide  
 
1H NMR (CDCl3, 400 MHz): δ 5.20-5.00 (m, 2 H, 2 x -CH); 4.68-4.54 (m, 2H,  
-CH2O
tBu); 4.43-4.29 (m, 2H, -CH2O
tBu); 3.90 and 3.84 (2 x s, 6H, 2 x –OCH3); 3.74-3.40 (m, 8H, 2 x –CH2-N
+(CH3)-CH2-
C15H31); 3.36, 3.35, 3.32, 3.29 (4 x s,  6H, -N
+(CH3)-); 1.80-1.50 (m, 8H, -CH2-CH2-N
+(CH3)-CH2-CH2-C14H27); 1.27 (bs, 
68H, -(CH2)13- + -N
+-(CH2)2-(CH2)8-(CH2)2-N
+-); 0.90 (t, 6H, J = 7.0 Hz, 2 x -CH3).  
 
 
Suppl. Info. 6 - 1H NMR spectra for dodecamethylenebis{[(2-tert-butyloxy-1-methoxycarbonyl)ethyl]-(hexadecyl) 
(methyl)  ammonium} diiodide. Intermediate product.  
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85 
Dodecamethylene bis{[(2-hydroxy-1-methoxycarbonyl)ethyl] (hexadecyl)(methyl)ammonium} 
Bis(trifluoroacetate) 
 
1H NMR (CDCl3, 400 MHz):δ = 4.74 (bs, 2H, 2 x -CH); 4.45-4.26 (m, 4H, 2 x -CH2OH); 4.14-3.44 (bs ,+ m, 14H  –OCH3 +  
-CH2-N
+(CH3)-CH2-C15H31), 3.41 and 3.37 (2 x bs 6H,  
-N+(CH3)-); 1.90-1.56 (m, 8H, -CH2-CH2-N
+(CH3)-CH2-CH2-C14H29); 1.38 and 1.27 (2 x bs, 68H, 2 x -(CH2)11- + -N
+-(CH2)2-
(CH2)8-(CH2)2-N
+-); 0.88 (t, 6H, J = 6.4 Hz, 2 x -CH3).  
 
 
Suppl. Info. 7 - 1H NMR spectra for dodecamethylene bis{[(2-hydroxy-1-methoxycarbonyl)ethyl] 
(hexadecyl)(methyl)ammonium} Bis(trifluoroacetate). Final product – (16Ser)2N12. 
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86 
Dimethyl (2S,17S)-Bis(tert-butyloxymethyl)-3,16-dioctadecyl-3,16-di-azaoctadecane-1,18-dioate 
 
1H NMR (CDCl3, 400 MHz): δ 3.73 (t, 2H, J = 7.6 Hz, 2 x –CH(H)-O
tBu); 3.71 (s, 6H, 2 x  
-OCH3); 3.58-3.46 (m, 4H, 2 x –CH(H)OH + 2 x -CH); 2.66-2.54 and 2.52-2.40 (2 m, 8H,  
N-CH2-(CH2)10-CH2-N and –N-CH2-C15H31), 1.50-1.37 (m, 8H, 2 x  -CH2-CH2-N-CH2-CH2-C16H33); 1.18 (bs, 76H, -(CH2)15- 
+ -N-(CH2)2-(CH2)8-(CH2)2-N-); 1.18 (18H, 2 x –C(CH3)3); 0.90 (t, 6H, J = 6.8 Hz, 2 x -CH3).  
 
 
Suppl. Info. 8 - 1H NMR spectra for dimethyl (2S,17S)-Bis(tert-butyloxymethyl)-3,16-dioctadecyl-3,16-di-
azaoctadecane-1,18-dioate. Intermediate product.  
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87 
Dodecamethylenebis{[(2-tert-butyloxy-1-methoxycarbonyl)ethyl]-(methyl) (octadecyl) ammonium} diiodide  
 
1H NMR (CDCl3, 400 MHz): δ 5.26-5.15 (m, 2 H, 2 x -CH); 4.28-4.05 (m, 4H,  
2 x -CH2O
tBu); 3.90-3.50 (m, 8H, 2 x –CH2-N
+(CH3)-CH2-C17H35); 3.84 and 3.83 (2 x s, 6H, 2 x -OCH3); 3.48, 3.47, 3.43, 
3.44 (4 x s, 6H, -N+(CH3)-); 1.95-1.65 (m, 8H, -CH2-CH2-N
+(CH3)-CH2-CH2-C16H33); 1.50-1.30 (m + bs, 76H, -(CH2)15- +-
N+-(CH2)2-(CH2)8-(CH2)2-N
+-); 0.88 (t, 6H, J = 6.8 Hz, 2 x -CH3).  
 
 
Suppl. Info. 9 - 1H NMR spectra for dodecamethylenebis{[(2-tert-butyloxy-1-methoxycarbonyl)ethyl]-(methyl) 
(octadecyl) ammonium} diiodide. Intermediate product. 
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88 
Dodecamethylene bis{[(2-hydroxy-1-methoxycarbonyl)ethyl] (methyl) (octadecyl)ammonium} 
Bis(trifluoroacetate) 
 
1H NMR (Acetone, 400 MHz):δ = 4.28, 4.72 (2 x bs, 2H, 2 x -CH); 4.46-4.14 (m, 4H,  
2 x -CH2OH); 3.96-3.60 (2 x bs + bs, 14H, 2 x –OCH3 + 2 x –CH2-N
+(CH3)-CH2-C17H34)  3.50, 3.49, 3.41(4) and 3.41 (4 x 
s, 6H, -N+(CH3)-); 2.10-1.80 (m, 8H, -CH2-CH2-N
+(CH3)-CH2-CH2-C16H32); 1.39 and 1.32 (bs, 76H, -(CH2)15- + -N
+-(CH2)2-
(CH2)8-(CH2)2-N
+-); 0.89 (t, 6H, J = 6.8 Hz, 2 x -CH3). 
 
 
 
Suppl. Info. 10 - 1H NMR spectra for dodecamethylene bis{[(2-hydroxy-1-methoxycarbonyl)ethyl] (methyl) 
(octadecyl)ammonium} Bis(trifluoroacetate). Final product – (18Ser)2N12.  
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89 
13C NMR (Acetone, 100 MHz): δ 168.5 and 167.6  (C=O); 74.2, 74.1 and 72.4 (-CH); 63.9, 63.8, 63.7(6) (-CH2-N
+-CH2-
C17H35); 59.8 and 59.7(8) (-CH2OH); 54.9 and 54.7 (-OCH3); 49.3 49.1 and 48.9 (-N
+(CH3)), [33.6, 31.8-30.1 and 27.9 
(N+(CH3)-CH2-(CH2)16-CH3)], 24.3 and 23.9 (-N
+-CH2-(CH2)8-N
+), 15.3 (-CH3). 
 
 
Suppl. Info. 11 – 13C NMR spectra for dodecamethylene bis{[(2-hydroxy-1-methoxycarbonyl)ethyl] (methyl) 
(octadecyl)ammonium} Bis(trifluoroacetate). Final product – (18Ser)2N12. 
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